Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone646-885-8505
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees32
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions
What is Y-mAbs Therapeutics' stock symbol?
Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."
How were Y-mAbs Therapeutics' earnings last quarter?
Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.05. View Y-mAbs Therapeutics' Earnings History.
When is Y-mAbs Therapeutics' next earnings date?
What price target have analysts set for YMAB?
6 analysts have issued 12 month target prices for Y-mAbs Therapeutics' shares. Their forecasts range from $26.00 to $40.00. On average, they expect Y-mAbs Therapeutics' stock price to reach $33.80 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price. View Analyst Price Targets for Y-mAbs Therapeutics.
What is the consensus analysts' recommendation for Y-mAbs Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Y-mAbs Therapeutics.
What are Wall Street analysts saying about Y-mAbs Therapeutics stock?
Here are some recent quotes from research analysts about Y-mAbs Therapeutics stock:
- 1. According to Zacks Investment Research, "Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. " (9/14/2019)
- 2. HC Wainwright analysts commented, "We have assessed Y-mAbs using a discounted cash flow (DCF)-based methodology, which yields a total enterprise value of $1.45B for the company based solely on the future sales of naxitamab and omburtamab." (6/10/2019)
Has Y-mAbs Therapeutics been receiving favorable news coverage?
Media coverage about YMAB stock has been trending negative on Thursday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Y-mAbs Therapeutics earned a news impact score of -2.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Y-mAbs Therapeutics.
Are investors shorting Y-mAbs Therapeutics?
Y-mAbs Therapeutics saw a drop in short interest in the month of August. As of August 15th, there was short interest totalling 771,900 shares, a drop of 10.0% from the July 15th total of 857,700 shares. Based on an average trading volume of 166,600 shares, the short-interest ratio is presently 4.6 days. Approximately 6.1% of the company's shares are short sold. View Y-mAbs Therapeutics' Current Options Chain.
Who are some of Y-mAbs Therapeutics' key competitors?
Some companies that are related to Y-mAbs Therapeutics include Blueprint Medicines (BPMC), The Medicines (MDCO), Nektar Therapeutics (NKTR), Allakos (ALLK), FibroGen (FGEN), Alkermes (ALKS), United Therapeutics (UTHR), Evotec (EVTCY), Mirati Therapeutics (MRTX), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS) and HUTCHISON CHINA/S (HCM).
What other stocks do shareholders of Y-mAbs Therapeutics own?
Who are Y-mAbs Therapeutics' key executives?
Y-mAbs Therapeutics' management team includes the folowing people:
- Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. (Age 48)
- Dr. Claus Juan Møller San Pedro, CEO & Director (Age 56)
- Mr. Bo Kruse, Exec. VP, Sec., Treasurer, CFO & Director (Age 47)
- Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 44)
- Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 68)
When did Y-mAbs Therapeutics IPO?
(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.
Who are Y-mAbs Therapeutics' major shareholders?
Y-mAbs Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.37%), Cormorant Asset Management LP (2.92%), Price T Rowe Associates Inc. MD (2.19%), Vanguard Group Inc. (1.43%), Artal Group S.A. (1.17%) and AXA (0.46%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, James Healy, Johan Wedell-Wedellsborg, Moller San Pedro Claus Juan and Thomas Gad. View Institutional Ownership Trends for Y-mAbs Therapeutics.
Which institutional investors are selling Y-mAbs Therapeutics stock?
YMAB stock was sold by a variety of institutional investors in the last quarter, including Tiverton Asset Management LLC, Flinton Capital Management LLC, Tyers Asset Management LLC, Neuburgh Advisers LLC and Meadow Creek Investment Management LLC. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Johan Wedell-Wedellsborg and Thomas Gad. View Insider Buying and Selling for Y-mAbs Therapeutics.
Which institutional investors are buying Y-mAbs Therapeutics stock?
YMAB stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Artal Group S.A., Cormorant Asset Management LP, Vanguard Group Inc., AXA, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC and Alps Advisors Inc.. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy and Moller San Pedro Claus Juan. View Insider Buying and Selling for Y-mAbs Therapeutics.
How do I buy shares of Y-mAbs Therapeutics?
Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Y-mAbs Therapeutics' stock price today?
One share of YMAB stock can currently be purchased for approximately $31.35.
How big of a company is Y-mAbs Therapeutics?
Y-mAbs Therapeutics has a market capitalization of $1.07 billion. The company earns $-43,270,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.View Additional Information About Y-mAbs Therapeutics.
What is Y-mAbs Therapeutics' official website?
How can I contact Y-mAbs Therapeutics?
Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]
MarketBeat Community Rating for Y-mAbs Therapeutics (NASDAQ YMAB)
MarketBeat's community ratings are surveys of what our community members think about Y-mAbs Therapeutics and other stocks. Vote "Outperform" if you believe YMAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe YMAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
